PCN31 - Eroltinib Plus Gemcitabine Compared With Gemcitabine Monotherapy In Patients With Pancreatic Cancer: A Real-World Analysis Of Korean Nationa-Wide Database

Abstract

This national population-based retrospective study aimed to evaluate the relative effectiveness of adding erlotinib to gemcitabine with pancreatic cancer patients compared to gemcitabine in real clinical practice. Patients was identified retrospectively using Korean National Health Insurance claims database who pancreatic cancer (ICD-10: C25) who initiated chemotherapy with gemcitabine or erlotinib between January 1, 2007 and December 31, 2012. To be included in the study population, patients were required to have a history of intervention for histologic or cytologic diagnosis within one year before chemotherapy. For homogeneity, patients were excluded if they have diagnosed with other cancers where gemcitabine is indicated or prior radiotherapy or surgical treatment. A total of 4,267 patients were included. Overall survival was not significantly longer in patients treated with gemcitabine/erlotinib (median 6.77 months for gemcitabine/erlotinib vs. 6.68 months for gemcitabine, p=0.0977). One-year survival rate was also not significantly different (27.0% vs. 27.3%; p=0.5988). Based on this relative effectiveness, incremental cost per life year gained over gemcitabine was estimated at USD 70,843.64 for gemcitabine plus erlotinib. Combination of gemcitabine/erlotinib of advanced pancreatic cancer is not more effective than gemcitabine monotherapy in a real-world setting. It does not provide reasonable cost-effectiveness over gemcitabine alone, and reimbursement strategies for pancreatic cancer in Korea could be reconsidered.